Programs

SAMiRNA is a modular, no-formulation micellar conjugate RNAi that enables delivery to organs beyond the liver. Around 80 nm in size and neutral in charge, SAMiRNA has excellent stability, meaning it can be delivered through versatile routes of administration

Immunology

Intravenous (IV) and subcutaneous (SC) administration delivers via Enhanced Permeability & Retention (EPR) mechanism to inflamed, fibrotic tissues and some solid tumors. This enables organ-agnostic tropism, meaning a single therapy could address various diseases across different organs and cell types.

Chest x-ray of a patient showing primary lung cancer in both right and left lobe of lung.

Pulmonology

Inhalation delivery of SAMiRNA penetrates the mucosal layers to achieve effective dose-dependent knockdown in the deep lung thanks to the micelle's neutral charge and high solubility. Our lung platform overcomes previous challenges of delivering RNAi safely and easily (via inhalation) to the entire lung, even to distal alveoli.

Skin showing hair follicles and sebaceous glands - Microscopic anatomy.jpg

Dermatology

Topical delivery of SAMiRNA enable development of RNAi-based treatments that are safe, effective, and easy to administer for certain dermatological conditions, as demonstrated in recent cosmeceutical studies. See below list of publications to learn more.

Publications

Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis. J Biol Chem. 2016 Mar 18;291(12):6433-46.
In vivo silencing of amphiregulin by a novel effective Self-Assembled-Micelle inhibitory RNA ameliorates renal fibrosis via inhibition of EGFR signals. Sci Rep. 2021 Jan 26;11(1):2191.
SAMiRNA Targeting Amphiregulin Alleviate Total-Body-Irradiation-Induced Renal Fibrosis. Radiat Res. 2022 May 1;197(5):471-479.
Four-Week Repeated Intravenous Dose Toxicity of Self-Assembled-Micelle Inhibitory RNA-Targeting Amphiregulin in Mice. Int J Toxicol. 2021 Oct;40(5):453-465.
Genotoxicity evaluation of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle for the treatment of fibrotic disease. Drug Chem Toxicol. 2021 Apr 27:1-7.
Safety pharmacology of self-assembled-micelle inhibitory RNA-targeting amphiregulin (SAMiRNA-AREG), a novel siRNA nanoparticle platform. Toxicol Rep. 2021 Mar 31;8:839-845.